Malerba M - Search Results

1

Effect of acute exacerbations on circulating endothelial, clotting and fibrinolytic markers in COPD patients.

Polosa R, Malerba M, Cacciola RR, Morjaria JB, Maugeri C, Prosperini G, Gullo R, Spicuzza L, Radaeli A, Di Maria GU. Polosa R, et al. Among authors: malerba m. Intern Emerg Med. 2013 Oct;8(7):567-74. doi: 10.1007/s11739-011-0636-1. Epub 2011 Jun 10. Intern Emerg Med. 2013. PMID: 21660493

2

COPD and the metabolic syndrome: an intriguing association.

Clini E, Crisafulli E, Radaeli A, Malerba M. Clini E, et al. Among authors: malerba m. Intern Emerg Med. 2013 Jun;8(4):283-9. doi: 10.1007/s11739-011-0700-x. Epub 2011 Oct 2. Intern Emerg Med. 2013. PMID: 21964838 Review.

3

Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial).

Malerba M, Ponticiello A, Radaeli A, Bensi G, Grassi V. Malerba M, et al. Pulm Pharmacol Ther. 2004;17(1):27-34. doi: 10.1016/j.pupt.2003.08.004. Pulm Pharmacol Ther. 2004. PMID: 14643168 Clinical Trial.

4

Therapeutic potential for novel ultra long-acting β2-agonists in the management of COPD: biological and pharmacological aspects.

Malerba M, Radaeli A, Morjaria JB. Malerba M, et al. Drug Discov Today. 2012 May;17(9-10):496-504. doi: 10.1016/j.drudis.2011.11.002. Epub 2011 Nov 18. Drug Discov Today. 2012. PMID: 22119310 Review.

5

Role of beta-blockers in patients with COPD: current perspective.

Malerba M, Montuschi P, Radaeli A, Pirisi M. Malerba M, et al. Drug Discov Today. 2015 Jan;20(1):129-35. doi: 10.1016/j.drudis.2014.09.005. Epub 2014 Sep 17. Drug Discov Today. 2015. PMID: 25238736 Review.

6

Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD--role of umeclidinium/vilanterol.

Malerba M, Morjaria JB, Radaeli A. Malerba M, et al. Int J Chron Obstruct Pulmon Dis. 2014 Jun 27;9:687-95. doi: 10.2147/COPD.S47792. eCollection 2014. Int J Chron Obstruct Pulmon Dis. 2014. PMID: 25061288 Free PMC article. Review.

7

Vilanterol trifenatate for the treatment of COPD.

Malerba M, Radaeli A, Montuschi P, Morjaria JB. Malerba M, et al. Expert Rev Respir Med. 2016 Jul;10(7):719-31. doi: 10.1080/17476348.2016.1184976. Epub 2016 May 25. Expert Rev Respir Med. 2016. PMID: 27143334 Review.

8

Analysis of common methodological flaws in the highest cited e-cigarette epidemiology research.

Hajat C, Stein E, Selya A, Polosa R; CoEHAR study group. Hajat C, et al. Intern Emerg Med. 2022 Apr;17(3):887-909. doi: 10.1007/s11739-022-02967-1. Epub 2022 Mar 24. Intern Emerg Med. 2022. PMID: 35325394 Free PMC article. Review.

9

Correction to: Analysis of common methodological flaws in the highest cited e-cigarette epidemiology research.

Hajat C, Stein E, Selya A, Polosa R; CoEHAR study group. Hajat C, et al. Intern Emerg Med. 2022 Aug;17(5):1561. doi: 10.1007/s11739-022-03022-9. Intern Emerg Med. 2022. PMID: 35704170 Free PMC article. No abstract available.

10

Biologic and pharmacologic therapies in clinical development for the inflammatory response in COPD.

Morjaria JB, Malerba M, Polosa R. Morjaria JB, et al. Among authors: malerba m. Drug Discov Today. 2010 May;15(9-10):396-405. doi: 10.1016/j.drudis.2010.03.001. Epub 2010 Mar 17. Drug Discov Today. 2010. PMID: 20223295 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

304 results

Search Page

Filters